$40.950
-0.229 (-0.56%)收盤時
VCEL 資訊
VCEL 事件
Company Reports Q1 Revenue of $68.4M
Reports Q1 revenue $68.4M, consensus $63.62M. Reports Q1 MACI revenue $56.4M, up from $46.3M last year. Reports Q1 burn care revenue up 91% vs. last year. "The Company delivered outstanding financial and business results in the first quarter, as we generated strong revenue and profit growth and achieved several key business objectives," said CEO Nick Colangelo.
Company Reaffirms FY26 Gross Margin Guidance of Approximately 75%
Consensus $323.43M. The company also reaffirmed its FY26 profitability guidance of a gross margin of approximately 75% and an adjusted EBITDA margin of approximately 27%.
MediWound and Vericel Sign $197M Contract
MediWound (MDWD) announced that Vericel (VCEL), its exclusive distributor of NexoBrid in North America, has been awarded a ten-year contract valued at up to $197M by the U.S. Biomedical Advanced Research and Development Authority, part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services. Vericel reported that the contract is for the procurement of NexoBrid, establishment and maintenance of a Vendor Managed Inventory system, design and validation of a U.S.-based manufacturing facility, and the development of a next generation formulation and additional indication for NexoBrid. Vericel further reported that the base period contract of $35M includes approximately $10M over the next 12 months for the initial procurement of NexoBrid for the U.S. Strategic National Stockpile and VMI establishment, funding for VMI-related services and initial development activities for a potential expanded NexoBrid indication for the treatment of blast trauma injuries. According to Vericel, the ten-year contract, effective as of April 1, also includes optional awards for additional NexoBrid procurement to expand the Strategic National Stockpile, further clinical development for a potential blast trauma indication, design and validation of a potential U.S.-based manufacturing facility and the development and procurement of a room temperature stable formulation of NexoBrid.
Vericel Receives FDA Approval for MACI Commercial Manufacturing
Vericel Corporation announced that the U.S. Food and Drug Administration, FDA, has granted approval for MACI commercial manufacturing at its state-of-the-art cell therapy manufacturing facility in Burlington, Massachusetts. The approval enables Vericel to begin commercial production of MACI at its new facility in the second quarter of 2026, positioning the Company to expand capacity to meet increasing demand for its restorative cartilage repair product and potentially commercialize MACI outside of the United States. "This FDA approval reflects a major achievement for Vericel and underscores the Company's operational and scientific expertise in complex cell therapy manufacturing," said Nick Colangelo, President and Chief Executive Officer of Vericel. "Bringing our Burlington facility online for commercial MACI production strengthens our supply chain and supports our mission to deliver innovative, high-quality therapies to patients. We look forward to building on this foundation as we continue to scale our business and create long-term value for patients and shareholders."
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。